Sunday, November 22, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > News > Astrazeneca reports 28% revenue growth on COVID windfall

Astrazeneca reports 28% revenue growth on COVID windfall

in News
Pfizer Seeks Emergency Use Authorization for Novel Covid-19 Oral Antiviral Candidate
Share on LinkedinShare on WhatsApp

UK-based pharmaceutical company Astrazeneca reported $25.4 billion in revenues in its 3Q21 earnings report, up 28% from 2020. A $2.2 billion dollar windfall in COVID vaccine revenues accounted for 11% of the rise in total revenues with the remaining 17% of growth coming from other medicines.

Gains in oncology which was up 16%, cardiovascular, renal and metabolism which was up 10% and respiratory and immunology which was up 12% accounted for the rest of the revenue rise over 2021.

According to the company it had released 1.5 billion doses of Vaxzevria, its COVID-19 vaccine, for global supply as of the end of September of which more than 145 million was distributed to the COVAX collaboration led by the WHO to ensure the availability of vaccines in low-income countries.

The company reported that one of its trial drugs, AZD7442, has had multiple positive Phase III results for COVID prevention and treatment, showing a 77% reduction of risk of symptomatic COVID-19 and a 50% risk reduction at 7 days from the disease’s onset. Astrazeneca also noted that Vaxzevria offers 91% protection against death due to the Delta variant.

Geographically growth was driven by the US market, which showed 53% year-over-year 3Q21 gains, flowed by Europe with 36% gains over the same period.

Tags: AstraZenecaCOVID windfallrevenue growth

Related Posts

Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment
News

Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment

Bending Spoons acquires Mailchimp in $3.68 billion deal
News

Bending Spoons acquires Mailchimp in $3.68 billion deal

PayPal appoints HP’s Enrique Lores as CEO
News

PayPal names Claire Bramley as new CFO

Google selects Bezos’ Blue Origin for AI space project
News

Google selects Bezos’ Blue Origin for AI space project

Anthropic sets $1 trillion IPO valuation target
News

Anthropic raises more than $81 billion in record IPO

Walmart beats predictions in latest quarter
News

Walmart raises outlook, anticipating a busy holiday season

U.S. officials order Nvidia to stop sales of AI chips to China
News

Nvidia shares rally following earnings beat

Target aims for non-alcoholic cocktail market ahead of the holiday season
News

Target reports its strongest sales growth in five years

Huang joins top CEOs on Trump’s China trip
News

Trump arrives in China for historic Xi, Putin meeting

The IMF-World Bank meetings commence in Washington
News

IMF chief gives stark warning on global economy 

No Result
View All Result

Recent Posts

  • Why are we so obsessed with the ’90s?
  • U.S. Loses Measles-Free Status After 26 Years
  • Plane clapping – joyful or deeply cringe?
  • The 4 themes shaping new manufacturing
  • Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.